Oxford Bioscience Partners
VC Fund
Boston, United States
Oxford Bioscience Partners is a VC fund in Boston focused on Health Care and Biotechnology. Oxford Bioscience Partners (OBP), established in 1992, is a venture capital firm that provides equity financing and management assistance to emerging, entrepreneurial-driven companies within the life sciences and healthcare sectors. While willing to consider an investment in a company at almost any stage, OBP primarily works with early-stagesituations. With approximately $1B of committed capital under management, OBP has invested in over 140 life science companies worldwide.
- Total investments:
- 110
- Last investment:
- Lead investor:
- 13%
- Fund size:
- $66M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Oxford Bioscience Partners invests in
Stages Oxford Bioscience Partners invests in
Countries Oxford Bioscience Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $3.5M–$26M
- Series B
- $10M–$48M
- Series C
- $5.6M–$50M
Investment Focus
Industry
- Health Care 40 (36%)
- Biotechnology 39 (35%)
- Pharmaceutical 19 (17%)
- Medical 18 (16%)
- Medical Device 16 (15%)
Stage
- Series B 31 (28%)
- Series C 18 (16%)
- Series A 17 (15%)
- Funding Round 12 (11%)
- Series D 9 (8%)
Country
- United States 58 (53%)
- Germany 1 (1%)
- Switzerland 1 (1%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alan G. Walton
Senior General Partner
|
Senior General Partner | Total investments: 3 | Find email | |
Alan Watson
Executive-in-Residence
|
Executive-in-Residence | Total investments: 0 | Find email | |
Julia Dan
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Manuel A. Navia
Executive-in-Residence
|
Executive-in-Residence | Total investments: 0 | Find email | |
Paul Tu
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Paperspace
|
Ceres, Inc. (Ceres) is an agricultural biotechnology company selling seeds to produce renewable biomass feedstocks. The Company’s large-scale commercial products are sweet sorghum varieties that can be used as a drop-in feedstock to extend the operating season of Brazilian sugarcane-to-ethanol mills. Its products include sweet sorghum, high biomasssorghum, switchgrass, miscanthus and row crops. Its energy crops can also be used for the production of second-generation biofuels and bio-based chemicals, including cellulosic ethanol, butanol, jet fuel, diesel-like molecules and gasoline-like molecules, from non-food biomass. Baseload utility scale electric power can also be generated from the biomass feedstocks grown from its seeds. Ceres has sold switchgrass and high biomass sorghum seeds in the United States under its Blade Energy Crops (Blade) brand. In January 2010, the Company incorporated a subsidiary, Ceres Sementes do Brasil Ltda. | Series F / Sep 27, 2021 | |
Ceres
|
Ceres applies genetic research and trait development to improve crop productivity, enhance quality characteristics, and support cultivation under varied environmental conditions. Its technology portfolio includes DNA-based trait solutions designed for integration across multiple crop types and end markets. Ceres also provides bioinformaticscapabilities through its Persephone software, which enables structured exploration and analysis of genomic data. | Series F / Sep 27, 2021 | |
Yolia Health
|
Yolia Health developed The True Vision Treatment or TVT, the 'Invisalign' for the eyes. A non-invasive treatment to correct vision problems like presbyopia without surgery. TVT is self-administered by the patient in his or her own home. It employs a combination of customized contact lenses (TVT Contacts) and specially formulatedeye drops (TVT Eye Drops). After only 5 days of treatment with TVT patients are able to stop using the TVT Contacts, TVT Eye Drops and their reading glasses for up to 12 months at a time before re-treatment with TVT is needed. What is even greater than correcting for presbyopia non-invasively, is correcting both eyes without compromising any distance vision. On the contrary, Yolia's treatment improves both near and distance vision, a unique feature no single other alternative can provide. ** Looking for sophisticated investors and key industry partners. | Series A / Jan 01, 2017 | |
CardioFocus
|
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, andinvestigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias.CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts. | Debt Financing / May 09, 2014 | |
Affinium Pharmaceuticals
|
Affinium Pharmaceuticals is a specialty pharmaceutical company focused on the development of novel anti-infective medicines. The Affinium FASII antibacterial programs constitute a new antibiotic franchise with the potential for multiple products targeting the FASII pathway. These programs include a broad base of long-term intellectual property:issued and pending composition of matter patents on potent orally available small molecule inhibitors for a new class of antibiotics with a unique mechanism of action, targeting an underexploited pathway. | $11.9M / Debt Financing / Sep 11, 2013 | |
Dicerna Pharmaceuticals
|
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The productcandidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.The company was founded in 2007 and is headquartered in Lexington, Massachusetts. | Series C / Jul 31, 2013 | |
Mitralign
|
Mitralign is a venture backed privately held company located in a suburb of Boston, MA. The company is developing an innovative catheter based technology for percutaneous treatment of functional mitral regurgitation. The novel Mitralign system emulates surgical annuloplasty as it delivers a series of surgical implants directly into the mitralannulus by means of a catheter. The implants are cinched together, thus reducing the size of the mitral valve annulus and the valve opening.Mitralign is funded by top tier venture capitalists and has two major cardiovascular device companies as investors. | $35M / Series D / May 16, 2012 | |
Glori Energy
|
Glori Energy's mission is to cleanly and safely recover billions of barrels of oil that are trapped in existing well reservoirs without having to drill a single new well. Glori partners with oil producers to install the AEROTM (Activated Environment for Recovery of Oil) System to significantly increase oil production. The AEROâ„¢ Systemprovides a new, viable low-cost option to cleanly and safely recover previously trapped oil and bring it to market. | $20M / Series C / Jan 24, 2012 | |
|
CardioFocus
|
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, andinvestigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias.CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts. | Series C / Feb 28, 2011 | |
SuperDimension
|
SuperDimension is a privately-held medical device company that develops and markets minimally-invasive pulmonology devices that enable the diagnosis and potentially the treatment of distal lung disease. Our product line, the i·LogicTM System, includes both capital equipment and disposables, addressing a total available market of more than 8million patients.Driven by our mission, "To be the world leader in the diagnosis and treatment of distal lung disease," we are focused on extending the capabilities of traditional bronchoscopy tools to help diagnose previously inaccessible lung lesions at an earlier stage when they may be easier to treat. | $15M / Debt Financing / Sep 07, 2010 | |
| See all 110 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Oxford Bioscience Partners invest in?
Oxford Bioscience Partners invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 110 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Oxford Bioscience Partners's check size?
Oxford Bioscience Partners typically joins rounds of $3.5M–$26M at Series A, $10M–$48M at Series B and $5.6M–$50M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Oxford Bioscience Partners participates in.
How do I contact Oxford Bioscience Partners?
Public channels for Oxford Bioscience Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Oxford Bioscience Partners?
The team at Oxford Bioscience Partners includes Alan G. Walton (Senior General Partner), Alan Watson (Executive-in-Residence) and Julia Dan (Venture Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
